{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:14:46Z","timestamp":1790252086253,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,7,2]],"date-time":"2010-07-02T00:00:00Z","timestamp":1278028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s11906-010-0116-4","type":"journal-article","created":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T04:08:19Z","timestamp":1277957299000},"page":"303-306","source":"Crossref","is-referenced-by-count":31,"title":["Aldosterone in the Pathogenesis of Chronic Kidney Disease and Proteinuria"],"prefix":"10.1007","volume":"12","author":[{"given":"Yee","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito M.","family":"Campese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,2]]},"reference":[{"key":"116_CR1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/ndt\/gfg233","volume":"18","author":"B Stengel","year":"2003","unstructured":"Stengel B, Billon S, Van Dijk PC, et al.: Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990\u20131999. Nephrol Dial Transplant 2003, 18:1824\u20131833.","journal-title":"Nephrol Dial Transplant"},{"key":"116_CR2","unstructured":"US Renal Data System: USRDS 2000 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000."},{"key":"116_CR3","unstructured":"Kotchen TA: Chapter 241. Hypertensive vascular disease. In Harrison\u2019s Principles of Internal Medicine, 17th edn. New York: McGraw-Hill; 2011. http:\/\/www.accessmedicine.com\/content.aspx?aID=2872428 ."},{"issue":"Suppl N","key":"116_CR4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/eurheartj\/16.suppl_N.92","volume":"16","author":"JP Bonvalet","year":"1995","unstructured":"Bonvalet JP, Alfaidy N, Farman N, Lombes M: Aldosterone: intracellular receptors in human heart. Eur Heart J 1995, 16(Suppl N):92\u201397","journal-title":"Eur Heart J"},{"key":"116_CR5","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0303-7207(95)03559-P","volume":"111","author":"BL Roland","year":"1995","unstructured":"Roland BL, Krozowski ZS, Funder JW: Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies. Mol Cell Endocrinol 1995, 111:R1\u2013R7.","journal-title":"Mol Cell Endocrinol"},{"key":"116_CR6","first-page":"1561","volume":"4","author":"L Kornel","year":"1982","unstructured":"Kornel L, Ramsay C, Kanamarlapudi N, et al.: Evidence for the presence in arterial walls of intracellular-molecular mechanism for action of mineralocorticoids. Clin Exp Hypertens A 1982, 4:1561\u20131582.","journal-title":"Clin Exp Hypertens A"},{"key":"116_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0735-1097(92)90130-F","volume":"20","author":"KT Weber","year":"1992","unstructured":"Weber KT, Anversa P, Armstrong PW, et al.: Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992, 20:3\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"116_CR8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","volume":"32","author":"NJ Brown","year":"1998","unstructured":"Brown NJ, Agirbasli MA, Williams GH, et al.: Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998, 32:965\u2013971.","journal-title":"Hypertension"},{"key":"116_CR9","first-page":"336","volume":"85","author":"NJ Brown","year":"2000","unstructured":"Brown NJ, Kim KS, Chen YQ, et al.: Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000, 85:336\u2013344.","journal-title":"J Clin Endocrinol Metab"},{"key":"116_CR10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","volume":"35","author":"Y Sun","year":"2000","unstructured":"Sun Y, Zhang J, Zhang JQ, Ramires FJ: Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000, 35:1078\u20131084.","journal-title":"Hypertension"},{"key":"116_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00004872-200105000-00001","volume":"19","author":"M Epstein","year":"2001","unstructured":"Epstein M: Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001, 19:829\u2013842.","journal-title":"J Hypertens"},{"key":"116_CR12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.20.1.67","volume":"20","author":"ME Ullian","year":"1992","unstructured":"Ullian ME, Schelling JR, Linas SL: Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992, 20:67\u201373.","journal-title":"Hypertension"},{"key":"116_CR13","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr CS, Lang CC, Hanson J, et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259\u20131265.","journal-title":"Am J Cardiol"},{"key":"116_CR14","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/0024-3205(82)90441-6","volume":"30","author":"MA Weber","year":"1982","unstructured":"Weber MA, Purdy RE: Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 1982, 30:2009\u20132017.","journal-title":"Life Sci"},{"key":"116_CR15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","volume":"14","author":"S Arima","year":"2003","unstructured":"Arima S, Kohagura K, Xu HL, et al.: Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003, 14:2255\u20132263.","journal-title":"J Am Soc Nephrol"},{"key":"116_CR16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","volume":"47","author":"M Nagase","year":"2006","unstructured":"Nagase M, Shibata S, Yoshida S, et al.: Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084\u20131093.","journal-title":"Hypertension"},{"key":"116_CR17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"116_CR18","first-page":"1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056\u20131064.","journal-title":"The RESOLVD Pilot Study Investigators. Circulation"},{"key":"116_CR19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","volume":"89","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Franceschini L, et al.: Relation of aldosterone \u201cescape\u201d despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002, 89:403\u2013407.","journal-title":"Am J Cardiol"},{"key":"116_CR20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11906-003-0087-9","volume":"5","author":"J Lakkis","year":"2003","unstructured":"Lakkis J, Lu WX, Weir MR: RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003, 5:408\u2013417.","journal-title":"Curr Hypertens Rep"},{"key":"116_CR21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ki.1978.114","volume":"14","author":"T Berl","year":"1978","unstructured":"Berl T, Katz FH, Henrich WL, et al.: Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978, 14:228\u2013235.","journal-title":"Kidney Int"},{"key":"116_CR22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","volume":"21","author":"RJ Hene","year":"1982","unstructured":"Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982, 21:98\u2013101.","journal-title":"Kidney Int"},{"key":"116_CR23","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/0002-9149(82)90390-3","volume":"49","author":"P Lijnen","year":"1982","unstructured":"Lijnen P, Staessen J, Fagard R, Amery A: Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982, 49:1561\u20131563.","journal-title":"Am J Cardiol"},{"key":"116_CR24","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"KJ Schjoedt","year":"2004","unstructured":"Schjoedt KJ, Andersen S, Rossing P, et al.: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47:1936\u20131939.","journal-title":"Diabetologia"},{"key":"116_CR25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ki.1992.45","volume":"41","author":"ZY Quan","year":"1992","unstructured":"Quan ZY, Walser M, Hill GS: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992, 41:326\u2013333.","journal-title":"Kidney Int"},{"key":"116_CR26","doi-asserted-by":"crossref","unstructured":"Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451\u2013458.","DOI":"10.1161\/01.HYP.31.1.451"},{"key":"116_CR27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232\u2013237.","journal-title":"Hypertension"},{"key":"116_CR28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063\u20131068.","journal-title":"J Clin Invest"},{"key":"116_CR29","first-page":"347","volume":"59","author":"H Goldblatt","year":"1934","unstructured":"Goldblatt H, Lynch J, Hanzal RF, Summerville WW: Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934, 59:347\u2013379.","journal-title":"Summerville WW: Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med"},{"key":"116_CR30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.HYP.26.1.101","volume":"26","author":"A Nicoletti","year":"1995","unstructured":"Nicoletti A, Heudes D, Hinglais N, et al.: Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension 1995, 26:101\u2013111.","journal-title":"Effect of losartan and spironolactone. Hypertension"},{"key":"116_CR31","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","volume":"16","author":"JC Aldigier","year":"2005","unstructured":"Aldigier JC, Kanjanbuch T, Ma LJ, et al.: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005, 16:3306\u20133314.","journal-title":"J Am Soc Nephrol"},{"key":"116_CR32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64\u201368.","journal-title":"Hypertension"},{"key":"116_CR33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A Sato","year":"2005","unstructured":"Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005, 18:44\u201349.","journal-title":"Am J Hypertens"},{"key":"116_CR34","doi-asserted-by":"crossref","unstructured":"Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000, 58(3):1219\u20131227.","DOI":"10.1046\/j.1523-1755.2000.00277.x"},{"key":"116_CR35","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.amjmed.2004.04.020","volume":"117","author":"K Nitta","year":"2004","unstructured":"Nitta K, Uchida K, Nihei H: Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases. Am J Med 2004, 117:444\u2013445.","journal-title":"Am J Med"},{"key":"116_CR36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","volume":"82","author":"RJ MacFadyen","year":"1999","unstructured":"MacFadyen RJ, Lee AF, Morton JJ, et al.: How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999, 82:57\u201361.","journal-title":"Heart"},{"key":"116_CR37","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","volume":"119","author":"M Epstein","year":"2006","unstructured":"Epstein M: Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119:912\u2013919.","journal-title":"Am J Med"},{"key":"116_CR38","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448\u20131456.","journal-title":"N Engl J Med"},{"key":"116_CR39","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940\u2013951.","journal-title":"Clin J Am Soc Nephrol"},{"key":"116_CR40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2215\/CJN.00120106","volume":"1","author":"MP Ponda","year":"2006","unstructured":"Ponda MP, Hostetter TH: Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:668\u2013677.","journal-title":"Clin J Am Soc Nephrol"},{"key":"116_CR41","doi-asserted-by":"crossref","unstructured":"Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006, 70:2116\u20132123.","DOI":"10.1038\/sj.ki.5001854"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-010-0116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-010-0116-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-010-0116-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:24Z","timestamp":1559434464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-010-0116-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,2]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["116"],"URL":"https:\/\/doi.org\/10.1007\/s11906-010-0116-4","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,2]]}}}